c9,t11-CLA in Children and Adolescents With Allergic Asthma
Launched by UNIVERSITY OF JENA · Dec 3, 2009
Trial Information
Current as of June 28, 2025
Completed
Keywords
ClinConnect Summary
In-vitro and animal studies strongly suggest that c9,t11-CLA reduces inflammatory processes in asthma-models. Aim of this study was to determine possible beneficial effects of orally administered c9,t11-CLA in children and adolescents with allergic bronchial asthma.
Thirty subjects (14 girls, 16 boys, age 6-18 years) were recruited from regular patients in the Clinic for Pediatric Allergology of the Friedrich Schiller University Jena. Informed consent was obtained from all participants/parents. 29 subjects completed the study.
The study was designed as a randomized and placebo-controlled ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • age 6-18 years
- • doctor-diagnosed bronchial asthma
- • allergic sensitization (house dust mite, grass pollen)
- • willingness to use only the recommended drugs
- • competence regarding the daily documentation of peak-flow data and symptoms
- Exclusion Criteria:
- • SIT within the last 2 years
- • primary and secondary immune deficiency
- • usage of systemic corticoids
- • intolerance against milk protein
- • alcohol and drug abuse
About University Of Jena
The University of Jena, a prominent research institution located in Germany, is dedicated to advancing medical science through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration and cutting-edge research, the university engages in a wide range of studies aimed at improving patient outcomes and enhancing healthcare practices. Its commitment to ethical standards and rigorous scientific methodology ensures that trials conducted under its auspices contribute valuable insights to the medical community. Through partnerships with various healthcare providers and industry stakeholders, the University of Jena strives to translate research findings into practical applications that benefit society at large.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Jena, Thuringia, Germany
Patients applied
Trial Officials
Gerhard Jahreis, Prof. Dr.
Principal Investigator
University of Jena, Dept. of Nutritional Physiology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials